Tags

Type your tag names separated by a space and hit enter

Aspirin and risk of renal cell cancer in Italy.
Eur J Cancer Prev 2010; 19(4):272-4EJ

Abstract

Aspirin and nonsteroidal anti-inflammatory drugs have been related to decreased risk of several cancers, but studies on the relation with the risk of renal cell cancer (RCC) are inconsistent. A case-control study of RCC was conducted in Italy between 1992 and 2004. Cases were 755 patients with incident, histologically confirmed RCC, and controls were 1297 patients in hospital for acute non-neoplastic conditions. Odds ratios (OR) and 95% confidence intervals (CI) for RCC were conditioned on center, sex, age, and year of interview, and adjusted for education, smoking, alcohol consumption, diabetes, and hypertension. Regular use of aspirin for at least 6 months was reported by 67 cases and 99 controls, corresponding to an OR of 0.98 (95% CI 0.69-1.38). The ORs were 0.91 (95% CI 0.55-1.50) in regular users for less than 3 years, and 1.04 (95% CI 0.67-1.63) in users for 3 years or longer; 0.47 (95% CI 0.20-1.12) when aspirin was used as analgesic and 1.10 (95% CI 0.75-1.62) when it was used for cardiovascular disease prevention. No significant heterogeneity was found for regular use of aspirin across strata of age and sex. This study, based on a large dataset, suggests that regular use of aspirin did not increase RCC risk.

Authors+Show Affiliations

Istituto di Ricerche Farmacologiche Mario Negri bIstituto di Statistica Medica e Biometria GA Maccacaro, Università di Milano, Milan, Italy. alessandra.tavani@marionegri.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20351553

Citation

Tavani, Alessandra, et al. "Aspirin and Risk of Renal Cell Cancer in Italy." European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), vol. 19, no. 4, 2010, pp. 272-4.
Tavani A, Scotti L, Bosetti C, et al. Aspirin and risk of renal cell cancer in Italy. Eur J Cancer Prev. 2010;19(4):272-4.
Tavani, A., Scotti, L., Bosetti, C., Dal Maso, L., Montella, M., Ramazzotti, V., ... La Vecchia, C. (2010). Aspirin and risk of renal cell cancer in Italy. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), 19(4), pp. 272-4. doi:10.1097/CEJ.0b013e3283394750.
Tavani A, et al. Aspirin and Risk of Renal Cell Cancer in Italy. Eur J Cancer Prev. 2010;19(4):272-4. PubMed PMID: 20351553.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aspirin and risk of renal cell cancer in Italy. AU - Tavani,Alessandra, AU - Scotti,Lorenza, AU - Bosetti,Cristina, AU - Dal Maso,Luigino, AU - Montella,Maurizio, AU - Ramazzotti,Valerio, AU - Negri,Eva, AU - Franceschi,Silvia, AU - La Vecchia,Carlo, PY - 2010/3/31/entrez PY - 2010/3/31/pubmed PY - 2011/2/17/medline SP - 272 EP - 4 JF - European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) JO - Eur. J. Cancer Prev. VL - 19 IS - 4 N2 - Aspirin and nonsteroidal anti-inflammatory drugs have been related to decreased risk of several cancers, but studies on the relation with the risk of renal cell cancer (RCC) are inconsistent. A case-control study of RCC was conducted in Italy between 1992 and 2004. Cases were 755 patients with incident, histologically confirmed RCC, and controls were 1297 patients in hospital for acute non-neoplastic conditions. Odds ratios (OR) and 95% confidence intervals (CI) for RCC were conditioned on center, sex, age, and year of interview, and adjusted for education, smoking, alcohol consumption, diabetes, and hypertension. Regular use of aspirin for at least 6 months was reported by 67 cases and 99 controls, corresponding to an OR of 0.98 (95% CI 0.69-1.38). The ORs were 0.91 (95% CI 0.55-1.50) in regular users for less than 3 years, and 1.04 (95% CI 0.67-1.63) in users for 3 years or longer; 0.47 (95% CI 0.20-1.12) when aspirin was used as analgesic and 1.10 (95% CI 0.75-1.62) when it was used for cardiovascular disease prevention. No significant heterogeneity was found for regular use of aspirin across strata of age and sex. This study, based on a large dataset, suggests that regular use of aspirin did not increase RCC risk. SN - 1473-5709 UR - https://www.unboundmedicine.com/medline/citation/20351553/Aspirin_and_risk_of_renal_cell_cancer_in_Italy_ L2 - http://Insights.ovid.com/pubmed?pmid=20351553 DB - PRIME DP - Unbound Medicine ER -